You are here

  • Home
  • Archive
  • Volume 70, Issue 6
  • Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial

Article info

Article menu
Clinical and epidemiological research
Extended report
Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial

Authors

  1. Correspondence to Dr Robert Spiera, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA; spierar{at}hss.edu
View Full Text

Citation

Spiera RF, Gordon JK, Mersten JN, et al
Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial
Annals of the Rheumatic Diseases 2011;70:1003-1009.

Publication history

  • Accepted January 23, 2011
  • First published March 11, 2011.
Online issue publication 
November 02, 2019

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This paper is freely available online under the BMJ Journals unlocked scheme, see http://ard.bmj.com/info/unlocked.dtl